Celyad Oncology SA · EURONEXT:CYAD
Celyad Oncology SA — Fact Sheet (March 2021)
1 slide from Celyad Oncology SA's fact sheet, March 2021
Slide 1: What is TIM?
What is TIM ? A major challenge using healthy donor cells when developing CAR T therapies is a potentially life-threatening condition called graft-versus-host disease (GvHD). GvHD occurs when allogeneic CAR T cells recognize the patient’s healthy tissues as foreign and attack them. This can be avoid